Skip to main content
Premium Trial:

Request an Annual Quote

Australian Cancer Center Licenses GenoLogics LIMS to Support NGS Workflows


Melbourne, Australia-based Peter MacCallum Cancer Center has licensed GenoLogics' Clarity laboratory information management system to support its next-generation and Sanger sequencing workflows, GenoLogics said this week.

Specifically, the center will use Clarity to maintain data integrity and manage its NGS workflows while adhering to regulatory requirements, GenoLogics said.

Andrew Fellowes, who heads molecular diagnostic development at the center, said in a statement that his team chose Clarity after reviewing other systems because of its ability to track patient sample data as well as to enforce clinical workflows.

He said the center will use Clarity's application programming interfaces to connect the new LIMS to its existing laboratory information system and also to its downstream analysis algorithms.

Other Clarity customers who are using the software to support their NGS workflows include Genomic Health (BI 2/22/2013) and Illumina's CLIA laboratory (BI 3/1/2013).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.